patients

Recommendations

Info

DNDi’s VISION To improve the quality of life and the health of people suffering from neglected diseases by using an alternative model to develop drugs for these diseases, and by ensuring equitable access to new and field-relevant health tools. In this not-for-profit model, driven by the public sector, a variety of players collaborate to raise awareness of the need to research and develop drugs for those neglected diseases that fall outside the scope of market-driven research and development (R&D). They also build public responsibility and leadership in addressing the needs of these patients. DNDi’s MISSION • To develop new drugs or new formulations of existing drugs for people living with neglected diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners. • DNDi’s primary focus has been the development of drugs for the most neglected diseases, such as human African trypanosomiasis (HAT, or sleeping sickness), leishmaniasis, and Chagas disease, while considering engagement in R&D projects for other neglected patients (e.g. malaria, paediatric HIV, filarial infections) and development of diagnostics and/or vaccines to address unmet needs that others are unable or unwilling to address. • In pursuing these goals, DNDi enables R&D networks built on global collaborations. While harnessing existing support capacities in countries where the diseases are endemic, DNDi contributes to strengthening capacities in a sustainable manner, including through know-how and technology transfers in the field of drug R&D for neglected diseases. • In order to address evolving needs of public health importance and maintain DNDi’s commitment to delivering on the objectives of the current portfolio of diseases, a dynamic portfolio approach has been adopted. This enables DNDi to take on new disease areas with various operating models, while completing objectives in current diseases.
The Drugs for Neglected Diseases initiative (DNDi) is a patient-needs driven, not-for-profit research and development (R&D) organization that develops safe, effective, and affordable medicines for the millions of neglected patients across the world. DNDi focuses on developing new treatments for the most neglected patients suffering from diseases such as human African trypanosomiasis (sleeping sickness), leishmaniasis, Chagas disease, filariasis, paediatric HIV, mycetoma, and hepatitis C. The initiative’s primary objective is to deliver a total of 16 to 18 treatments by 2023 and to establish a strong R&D portfolio for these diseases. CONTENTS 2015 ANNUAL REPORT VISION, MISSION & STRATEGY 4 R&D MODEL & PORTFOLIO 14 STRENGTHENING EXISTING CAPACITIES 56 ADVOCACY, 62 COMMUNICATIONS & FUNDRAISING FINANCIAL REPORT 68 Cover photo: A mobile team of the National Control Programme for sleeping sickness screens a young boy for sleeping sickness, in Mpata village, Democratic Republic of the Congo. DNDi Annual Report 2015 › 3
Page 1: From neglected diseases to neglecte
Page 5 and 6: STRATEGY An unchanged vision, an ex
Page 7 and 8: STRATEGY DNDi’s portfolio progres
Page 9 and 10: STRATEGY GARD: A new partnership to
Page 11 and 12: STRATEGY REGIONAL OFFICE BOARDS DND
Page 13 and 14: STRATEGY Stabilization of the Socia
Page 15 and 16: R&D MODEL & PORTFOLIO pre-clinical
Page 17 and 18: R&D MODEL & PORTFOLIO New treatment
Page 19 and 20: R&D MODEL & PORTFOLIO DISCOVERY Dru
Page 21 and 22: R&D MODEL & PORTFOLIO with similar
Page 23 and 24: HUMAN AFRICAN TRYPANOSOMIASIS / SLE
Page 25 and 26: HUMAN AFRICAN TRYPANOSOMIASIS / SLE
Page 27 and 28: LEISHMANIASIS R&D MODEL & PORTFOLIO
Page 37 and 38: CHAGAS DISEASE R&D MODEL & PORTFOLI
Page 39 and 40: CHAGAS DISEASE R&D MODEL & PORTFOLI
Page 41 and 42: › The helminth worms responsible
Page 43 and 44: FILARIAL DISEASES R&D MODEL & PORTF
Page 45 and 46: PAEDIATRIC HIV R&D MODEL & PORTFOLI
Page 47 and 48: PAEDIATRIC HIV R&D MODEL & PORTFOLI
Page 49 and 50: HEPATITIS C R&D MODEL & PORTFOLIO W
Page 51 and 52: Almina, a mycetoma patient, showing
Page 53 and 54:
ASAQ and ASMQ, the two antimalarial
Page 55 and 56:
R&D MODEL & PORTFOLIO Development a
Page 57 and 58:
STRENGTHENING EXISTING CAPACITIES B
Page 59 and 60:
STRENGTHENING EXISTING CAPACITIES H
Page 61 and 62:
STRENGTHENING EXISTING CAPACITIES S
Page 63 and 64:
ADVOCACY, COMMUNICATIONS & FUNDRAIS
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
FINANCIAL REPORT Financial Report 2
Page 71 and 72:
FINANCIAL REPORT FUNDS FLOW STATEME
Page 73 and 74:
FINANCIAL REPORT DNDi legal framewo
Page 75 and 76:
FINANCIAL REPORT l) Capital of the
Page 77 and 78:
FINANCIAL REPORT 4 TANGIBLE FIXED A
Page 79 and 80:
FINANCIAL REPORT 7 INCOME a) Deferr
Page 81 and 82:
FINANCIAL REPORT GHIT (4) (Restrict
Page 83 and 84:
FINANCIAL REPORT MAIN R&D PARTNERS
Page 85 and 86:
FINANCIAL REPORT 10 ADVOCACY, FUNDR
Page 87 and 88:
FINANCIAL REPORT 15 SWISS FRANC EQU
Page 89 and 90:
Drugs for Neglected Diseases initia
Page 91 and 92:
DNDi Team Copyright: Drugs for Negl
show all

patients

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?